The US Trade Representative opened a Section 301 investigation into Germany on June 18, targeting what it calls systematic underpayment for innovative pharmaceutical products. The move represents a sharp escalation in an already tense transatlantic trade relationship, and it puts one of Europe’s most important export sectors squarely in the crosshairs.

What the investigation actually means

A Section 301 investigation is the US trade policy equivalent of loading a gun. It doesn’t fire tariffs immediately, but it creates the legal framework to do so. The USTR is now formally examining whether Germany’s pharmaceutical pricing policies constitute an unfair trade practice that harms American industry.

EU pharmaceutical exports to the US were valued at $127 billion in 2024, making the sector the single largest EU export category to America. Germany, with its outsized pharmaceutical industry anchored by companies like Bayer and Boehringer Ingelheim, accounts for a significant chunk of that figure and has historically run substantial trade surpluses with the US in this sector.

Proposed tariffs could reach up to 100% on certain patented products if US production is not prioritized.

This didn’t come out of nowhere

The investigation builds on a pattern of escalating pressure that has been developing for more than a year. Section 232 investigations launched in 2025 already characterized pharmaceutical imports as a national security concern, a framing that gave the administration broad authority to impose tariffs without congressional approval.

In May 2026, the US exerted direct diplomatic pressure on the German ambassador concerning drug pricing.

What this means for markets and investors

European pharmaceutical companies with significant US revenue exposure face the most immediate uncertainty. If tariffs materialize at anything close to the proposed levels, these firms would need to choose between absorbing the cost hit to margins, passing it along to US customers, or accelerating plans to manufacture domestically.

The broader US-EU trade relationship is also at stake. Pharmaceuticals represent the single largest category of EU exports to America, and retaliatory measures from Brussels are not out of the question.

Section 301 investigations typically involve a public comment period, industry consultations, and a formal determination before any tariffs take effect, creating an extended window of uncertainty for pharmaceutical stocks on both sides of the Atlantic.